Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282411 · ClinicalTrials.gov registry record
Anatomic Outcomes Following Ozurdex Injections
A clinical trial, sponsored by Barnes Retina Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT01282411: Completed study, sponsored by Barnes Retina Institute.
NCT01282411 is a clinical trial that has completed, run by Barnes Retina Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282411 has completed, sponsored by Barnes Retina Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Ozurdex(TM) has recently been FDA approved for use in macular edema secondary to retinal vein occlusion. It remains unclear how quickly the drug works and for how long as the initial studies did not have frequent anatomic monitoring. This study will utilize frequent Spectral domain OCT imaging to better understand the onset of treatment effectiveness and duration of action on the anatomic thickness of the retina, in addition to distinguishing structural abnormalities of responders from non-responders.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-07 |
What the finished NCT01282411 record still lists
NCT01282411 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01282411 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01282411 about?
NCT01282411 is a clinical study titled "Anatomic Outcomes Following Ozurdex Injections". Ozurdex(TM) has recently been FDA approved for use in macular edema secondary to retinal vein occlusion. It remains unclear how quickly the drug works and for how long as the initial studies did not have frequent anatomic monitoring. This study will utilize frequent Spectral domain OCT imaging to be...
What is the current status of trial NCT01282411?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2010-02. Estimated completion is 2011-07.
Who is sponsoring clinical trial NCT01282411?
This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia